Literature DB >> 16318165

Determinants of states' allocations of the master settlement agreement payments.

Frank A Sloan1, Emily Streyer Carlisle, John R Rattliff, Justin Trogdon.   

Abstract

To determine which factors influence states' allocation decisions for the tobacco Master Settlement Agreement and the four individual settlements' annual payments, including the decision to securitize, we analyzed the effects of voter characteristics, political parties, interest groups, prior spending on public tobacco control programs, and state fiscal health on per capita settlement funds allocated to tobacco-control, health, and other programs. Tobacco-producing states and those with high proportions of conservative Democrats or elderly, black, Hispanic, or wealthy people tended to spend less on tobacco control. Education and medical lobbies had strong positive influences on per capita allocations for tobacco-control and health-related programs. State fiscal crises affected amounts spent by states from settlement funds as well as the probability of securitizing future cash flows from the settlements.

Entities:  

Mesh:

Year:  2005        PMID: 16318165     DOI: 10.1215/03616878-30-4-643

Source DB:  PubMed          Journal:  J Health Polit Policy Law        ISSN: 0361-6878            Impact factor:   2.265


  3 in total

1.  What factors predict the passage of state-level e-cigarette regulations?

Authors:  Johanna Catherine Maclean; Melissa Oney; Joachim Marti; Jody Sindelar
Journal:  Health Econ       Date:  2018-02-22       Impact factor: 3.046

2.  Master Settlement Agreement (MSA) spending and tobacco control efforts.

Authors:  Jayani Jayawardhana; W David Bradford; Walter Jones; Paul J Nietert; Gerard Silvestri
Journal:  PLoS One       Date:  2014-12-15       Impact factor: 3.240

3.  Tobacco cessation quitline spending in 2005 and 2006: what state-level factors matter?

Authors:  Paula A Keller; Eric J Beyer; Timothy B Baker; Linda A Bailey; Michael C Fiore
Journal:  Int J Environ Res Public Health       Date:  2009-01-13       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.